{
    "organizations": [],
    "uuid": "f9facada1aad54aa4e628c601a1936ca231d4f84",
    "author": "",
    "url": "https://www.reuters.com/article/brief-immunocellular-therapeutics-announ/brief-immunocellular-therapeutics-announces-review-of-strategic-alternatives-idUSASB0C6WS",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunocellular Therapeutics Announces Review Of Strategic Alternatives",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 11 AM / Updated 9 minutes ago BRIEF-Immunocellular Therapeutics Announces Review Of Strategic Alternatives Reuters Staff Feb 22 (Reuters) - Immunocellular Therapeutics Ltd: * IMMUNOCELLULAR THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES * IMMUNOCELLULAR THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES * IMMUNOCELLULAR THERAPEUTICS - RETAINED LADENBURG THALMANN & CO AS STRATEGIC FINANCIAL ADVISOR TO ASSIST IN REVIEW OF BUSINES, ASSETS * IMMUNOCELLULAR THERAPEUTICS - REVIEW OF STRATEGIC OPPORTUNITIES COULD INCLUDE POTENTIAL SALE OR MERGER OF COMPANY Source text for Eikon: Further company coverage:",
    "published": "2018-02-22T13:11:00.000+02:00",
    "crawled": "2018-02-22T13:30:32.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "review",
        "strategic",
        "alternative",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "immunocellular",
        "therapeutic",
        "ltd",
        "immunocellular",
        "therapeutic",
        "announces",
        "review",
        "strategic",
        "alternative",
        "immunocellular",
        "therapeutic",
        "announces",
        "review",
        "strategic",
        "alternative",
        "immunocellular",
        "therapeutic",
        "retained",
        "ladenburg",
        "thalmann",
        "co",
        "strategic",
        "financial",
        "advisor",
        "assist",
        "review",
        "busines",
        "asset",
        "immunocellular",
        "therapeutic",
        "review",
        "strategic",
        "opportunity",
        "could",
        "include",
        "potential",
        "sale",
        "merger",
        "company",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}